BioSpace News Archive

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that data from the GEMINI Phase 3 trial of AXS-05 in major depressive disorder will be presented in oral and poster sessions at the 2020 Annual Meeting of the American Society for Clinical Psychopharmacology, to be held virtually, May 29-30.

OraSure Technologies, Inc., a leader in point of care diagnostic tests and specimen collection and stabilization devices, and microbiome laboratory and analytical services, announced that it has entered into a definitive agreement to acquire privately owned UrSure, Inc. for cash.

AVEO Oncology announced that the Phase 1b/2 DEDUCTIVE clinical trial evaluating FOTIVDA®, the Company’s once-daily, potent and selective next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with IMFINZI®...

Tangen Biosciences, Inc., announced that the company and LabWare, Inc. agreed to enter into an exclusive partnership whereby LabWare will distribute Tangen’s GeneSpark™ device as part of the LabWare’s Portable Disease Surveillance Lab kit in response to the COVID-19 pandemic.

At the virtual ASMS 2020 Reboot conference, Bruker Corporation (Nasdaq: BRKR) today announces a major advance in matrix-assisted laser desorption ionization (MALDI) with the launch of the world’s first commercial MALDI-2 post-ionization (PI) source, which is now available as an option on the timsTOF fleXTM ESI/MALDI mass spectrometer.

New Phase 2 trial in EGJ cancer planned for 1H 2021, after first two patients treated responded to next-generation ADP-A2M4CD8 therapy

NextCure, Inc. announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology Annual Meeting.

Data show immune responses occur rapidly after only two vaccinations and can be sustained for more than one year

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced data from an ongoing phase 1 dose escalation study of TTI-622 in patients with advanced relapsed or refractory lymphoma.

Elucidation of CD68 as a Downstream Target of Adenosine Refines Adenosine Gene Signature into a Practical Pathology Test Provides Opportunity to Further Enrich Patient Selection for Responders